Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 M3RNA Drives Targeted Gene Delivery in Acute Myocardial Infarction.

Literature DB >> 30047313

M³RNA Drives Targeted Gene Delivery in Acute Myocardial Infarction.

Raman Deep Singh^1,2, Matthew L Hillestad^1,2, Christopher Livia^1,2,3, Mark Li^1,2,3, Alexey E Alekseev^1,2,4, Tyra A Witt^1,2, Paul G Stalboerger^1,2, Satsuki Yamada^1,2, Andre Terzic^1,2,3, Atta Behfar^1,2,3.

Abstract

IMPACT STATEMENT: The M3RNA (microencapsulated modified messenger RNA) platform is an approach to deliver messenger RNA (mRNA) in vivo, achieving a nonintegrating and viral-free approach to gene therapy. This technology was, in this study, tested for its utility in the myocardium, providing a unique avenue for targeted gene delivery into the freshly infarcted myocardial tissue. This study provides the evidentiary basis for the use of M3RNA in the heart through depiction of its performance in cultured cells, healthy rodent myocardium, and acutely injured porcine hearts. By testing the technology in large animal models of infarction, compatibility of M3RNA with current coronary intervention procedures was verified.

Entities: Disease

Keywords: MRNA; gene therapy; myocardial infarction; targeted nucleotide delivery

Mesh：

Substances：

Year: 2018 PMID： 30047313 PMCID： PMC6352545 DOI： 10.1089/ten.TEA.2017.0445

Source DB: PubMed Journal: Tissue Eng Part A ISSN： 1937-3341 Impact factor: 3.845

71 in total

1. Therapeutic delivery of mRNA: the medium is the message.

Authors: R Scott McIvor
Journal: Mol Ther Date: 2011-05 Impact factor: 11.454

Review 2. Inflammation and wound healing: the role of the macrophage.

Authors: Timothy J Koh; Luisa Ann DiPietro
Journal: Expert Rev Mol Med Date: 2011-07-11 Impact factor: 5.600

3. Repeated and targeted transfer of angiogenic plasmids into the infarcted rat heart via ultrasound targeted microbubble destruction enhances cardiac repair.

Authors: Hiroko Fujii; Shu-Hong Li; Jun Wu; Yasuo Miyagi; Terrence M Yau; Harry Rakowski; Kensuke Egashira; Jian Guo; Richard D Weisel; Ren-Ke Li
Journal: Eur Heart J Date: 2010-12-31 Impact factor: 29.983

4. Sustained expression of circulating human alpha-1 antitrypsin reduces inflammation, increases CD4+FoxP3+ Treg cell population and prevents signs of experimental autoimmune encephalomyelitis in mice.

Authors: Sandhya Subramanian; Galit Shahaf; Eyal Ozeri; Lisa M Miller; Arthur A Vandenbark; Eli C Lewis; Halina Offner
Journal: Metab Brain Dis Date: 2011-03-25 Impact factor: 3.584

5. Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice.

Authors: Maulik D Majmudar; Edmund J Keliher; Timo Heidt; Florian Leuschner; Jessica Truelove; Brena F Sena; Rostic Gorbatov; Yoshiko Iwamoto; Partha Dutta; Gregory Wojtkiewicz; Gabriel Courties; Matt Sebas; Anna Borodovsky; Kevin Fitzgerald; Marc W Nolte; Gerhard Dickneite; John W Chen; Daniel G Anderson; Filip K Swirski; Ralph Weissleder; Matthias Nahrendorf
Journal: Circulation Date: 2013-04-24 Impact factor: 29.690

6. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates.

Authors: Maria Frank-Kamenetsky; Aldo Grefhorst; Norma N Anderson; Timothy S Racie; Birgit Bramlage; Akin Akinc; David Butler; Klaus Charisse; Robert Dorkin; Yupeng Fan; Christina Gamba-Vitalo; Philipp Hadwiger; Muthusamy Jayaraman; Matthias John; K Narayanannair Jayaprakash; Martin Maier; Lubomir Nechev; Kallanthottathil G Rajeev; Timothy Read; Ingo Röhl; Jürgen Soutschek; Pamela Tan; Jamie Wong; Gang Wang; Tracy Zimmermann; Antonin de Fougerolles; Hans-Peter Vornlocher; Robert Langer; Daniel G Anderson; Muthiah Manoharan; Victor Koteliansky; Jay D Horton; Kevin Fitzgerald
Journal: Proc Natl Acad Sci U S A Date: 2008-08-11 Impact factor: 11.205

7. Pharmacoinvasive and Primary Percutaneous Coronary Intervention Strategies in ST-Elevation Myocardial Infarction (from the Mayo Clinic STEMI Network).

Authors: Konstantinos C Siontis; Gregory W Barsness; Ryan J Lennon; Jody L Holmen; R Scott Wright; Malcolm R Bell; Bernard J Gersh
Journal: Am J Cardiol Date: 2016-04-06 Impact factor: 2.778

8. Inhibition of caveolar uptake, SV40 infection, and beta1-integrin signaling by a nonnatural glycosphingolipid stereoisomer.

Authors: Raman Deep Singh; Eileen L Holicky; Zhi-jie Cheng; Seong-Youl Kim; Christine L Wheatley; David L Marks; Robert Bittman; Richard E Pagano
Journal: J Cell Biol Date: 2007-03-19 Impact factor: 10.539

9. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial.

Authors: Barry Greenberg; Javed Butler; G Michael Felker; Piotr Ponikowski; Adriaan A Voors; Akshay S Desai; Denise Barnard; Alain Bouchard; Brian Jaski; Alexander R Lyon; Janice M Pogoda; Jeffrey J Rudy; Krisztina M Zsebo
Journal: Lancet Date: 2016-01-21 Impact factor: 79.321

M³RNA Drives Targeted Gene Delivery in Acute Myocardial Infarction.

1. Therapeutic delivery of mRNA: the medium is the message.

Review 2. Inflammation and wound healing: the role of the macrophage.

3. Repeated and targeted transfer of angiogenic plasmids into the infarcted rat heart via ultrasound targeted microbubble destruction enhances cardiac repair.

4. Sustained expression of circulating human alpha-1 antitrypsin reduces inflammation, increases CD4+FoxP3+ Treg cell population and prevents signs of experimental autoimmune encephalomyelitis in mice.

5. Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice.

6. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates.

7. Pharmacoinvasive and Primary Percutaneous Coronary Intervention Strategies in ST-Elevation Myocardial Infarction (from the Mayo Clinic STEMI Network).

8. Inhibition of caveolar uptake, SV40 infection, and beta1-integrin signaling by a nonnatural glycosphingolipid stereoisomer.

9. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial.

Review 10. Endocytosis and exocytosis of nanoparticles in mammalian cells.

1. Emerging nanotechnologies in cardiovascular medicine.

Review 2. mRNA-Based Protein Replacement Therapy for the Heart.

Review 3. Modified mRNA as a Therapeutic Tool for the Heart.

Review 4. Mass Customized Outlook for Regenerative Heart Failure Care.

5. Optimizing Modified mRNA In Vitro Synthesis Protocol for Heart Gene Therapy.

6. A preview of selected articles.

7. Brachyury engineers cardiac repair competent stem cells.